CN111542373A - 通过利用雄激素剥夺疗法施用醋酸阿比特龙加泼尼松治疗前列腺癌的方法 - Google Patents

通过利用雄激素剥夺疗法施用醋酸阿比特龙加泼尼松治疗前列腺癌的方法 Download PDF

Info

Publication number
CN111542373A
CN111542373A CN201880079993.2A CN201880079993A CN111542373A CN 111542373 A CN111542373 A CN 111542373A CN 201880079993 A CN201880079993 A CN 201880079993A CN 111542373 A CN111542373 A CN 111542373A
Authority
CN
China
Prior art keywords
patients
abiraterone acetate
prostate cancer
prednisone
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880079993.2A
Other languages
English (en)
Chinese (zh)
Inventor
N.特兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson Oncology Inc
Original Assignee
Johnson Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson Oncology Inc filed Critical Johnson Oncology Inc
Publication of CN111542373A publication Critical patent/CN111542373A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880079993.2A 2017-10-11 2018-02-08 通过利用雄激素剥夺疗法施用醋酸阿比特龙加泼尼松治疗前列腺癌的方法 Pending CN111542373A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762570781P 2017-10-11 2017-10-11
US62/570781 2017-10-11
PCT/US2018/017438 WO2019074536A1 (en) 2017-10-11 2018-02-08 METHODS OF TREATING PROSTATE CANCER BY ADMINISTERING ABIRATERONE ACETATE AND PREDNISONE WITH ANDROGENIC SEPARATION THERAPY

Publications (1)

Publication Number Publication Date
CN111542373A true CN111542373A (zh) 2020-08-14

Family

ID=61283312

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880079993.2A Pending CN111542373A (zh) 2017-10-11 2018-02-08 通过利用雄激素剥夺疗法施用醋酸阿比特龙加泼尼松治疗前列腺癌的方法

Country Status (16)

Country Link
US (2) US20190105332A1 (enExample)
EP (1) EP3694604A1 (enExample)
JP (1) JP2020536903A (enExample)
KR (1) KR20200068689A (enExample)
CN (1) CN111542373A (enExample)
AU (1) AU2018347804A1 (enExample)
BR (1) BR112020007090A2 (enExample)
CA (1) CA3077678A1 (enExample)
EA (1) EA202090916A1 (enExample)
IL (1) IL273826A (enExample)
JO (1) JOP20200072A1 (enExample)
MA (1) MA50341A (enExample)
MX (1) MX2020003830A (enExample)
PH (1) PH12020550151A1 (enExample)
UA (1) UA124865C2 (enExample)
WO (1) WO2019074536A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20190403A1 (es) 2016-07-29 2019-03-13 Janssen Pharmaceutica Nv Metodos para tratar el cancer de prostata
UA129105C2 (uk) 2017-10-16 2025-01-15 Арагон Фармасьютикалз, Інк. Антиандрогени для лікування неметастатичного резистентного до кастрації раку передміхурової залози
CA3177137A1 (en) * 2020-05-08 2021-11-11 Janssen Pharmaceutica Nv Treatments of prostate cancer with combinations of abiraterone acetate and niraparib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102898495A (zh) * 2012-11-12 2013-01-30 浙江神洲药业有限公司 醋酸阿比特龙酯的制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102898495A (zh) * 2012-11-12 2013-01-30 浙江神洲药业有限公司 醋酸阿比特龙酯的制备方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KARIM FIZAZI等: "Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer", THE NEW ENGLAND JOURNAL OF MEDICINE *
MARK A. PERLMUTTER等: "Androgen Deprivation Therapy in the Treatment of Advanced Prostate Cancer", REVIEWS IN UROLOGY *
吴开杰;: "New England Journal of Medicine:阿比特龙在转移性激素敏感性前列腺癌中的应用――LATITUDE试验中期结果发布", 现代泌尿外科杂志 *
周爱萍;房虹;李长岭;孙燕;: "去势抗拒前列腺癌治疗新药醋酸阿比特龙", 中国新药杂志 *

Also Published As

Publication number Publication date
MA50341A (fr) 2020-08-19
IL273826A (en) 2020-05-31
UA124865C2 (uk) 2021-12-01
MX2020003830A (es) 2020-11-06
US20190105332A1 (en) 2019-04-11
BR112020007090A2 (pt) 2020-09-24
PH12020550151A1 (en) 2021-02-08
EA202090916A1 (ru) 2020-12-11
KR20200068689A (ko) 2020-06-15
AU2018347804A1 (en) 2020-04-16
CA3077678A1 (en) 2019-04-18
JOP20200072A1 (ar) 2020-04-29
US20200069704A1 (en) 2020-03-05
WO2019074536A1 (en) 2019-04-18
JP2020536903A (ja) 2020-12-17
EP3694604A1 (en) 2020-08-19

Similar Documents

Publication Publication Date Title
JP7201694B2 (ja) 非転移性去勢抵抗性前立腺癌の治療のための抗アンドロゲン剤
US20200069704A1 (en) Methods Of Treating Prostate Cancer
KR20210153038A (ko) 전이성 거세-민감성 전립선암의 치료를 위한 항안드로겐
TW202302084A (zh) 以安森司坦和帕博西尼治療乳癌
US20210137903A1 (en) Anti-androgens for the treatment of prostrate cancer
US20250177414A1 (en) Combination therapies for treatment of breast cancer
HK40116445A (en) Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2025027138A9 (en) Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer
CN117580572A (zh) 用安森司坦和帕博西尼治疗乳腺癌
JP2025506402A (ja) 転移性去勢抵抗性前立腺癌及びｈｒｒ変化を有する患者における臨床アウトカムを改善するためのニラパリブ及び酢酸アビラテロン＋プレドニゾン
WO2020144647A1 (en) Pharmaceutical composition comprising apalutamide dispersed in apple sauce
WO2014193589A1 (en) Cancer treatment method

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200814

WD01 Invention patent application deemed withdrawn after publication